Ventyx Biosciences, Inc. (VTYX) is a publicly traded company in the Unknown sector. Across all available filings, 16 corporate insiders have executed 262 transactions totaling $159.2M, demonstrating a bearish sentiment with -$119.2M in net insider flow. The most recent transaction on Dec 18, 2025 involved a sale of 12,675 shares valued at $97.9K.
No significant insider buying has been recorded for VTYX in the recent period.
No significant insider selling has been recorded for VTYX in the recent period.
Based on recent SEC filings, insider sentiment for VTYX is bearish with an Insider Alignment Score of 13/100 and a net flow of -$119.2M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Ventyx Biosciences, Inc. (VTYX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 16 insiders are actively trading VTYX stock, having executed 262 transactions in the past 90 days. The most active insider is Somu Subramaniam (Executive), who has made 41 transactions totaling $45.6M.
Get notified when executives and directors at VTYX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 18, 2025 | Nuss John | Executive | Sale | 12,675 | $7.72 | $97.9K | |
| Dec 18, 2025 | Mohan Raju | Executive | Sale | 47,345 | $7.72 | $365.5K | |
| Dec 17, 2025 | Nuss John | Executive | Option Exercise | 34,930 | $N/A | $0 | |
| Dec 17, 2025 | Mohan Raju | Executive | Option Exercise | 116,668 | $N/A | $0 | |
| Nov 17, 2025 | Gonzales Roy | Executive | Award | 1,767 | $1.03 | $1.8K | |
| Nov 17, 2025 | S. Forman Mark | Executive | Award | 3,000 | $1.03 | $3.1K | |
| Jun 24, 2024 | Subramaniam Somu | Executive | Other | 641,327 | $N/A | $0 | |
| Jun 24, 2024 | III Gp Llc Nsv Partners | Executive | Other | 641,327 | $N/A | $0 | |
| Jun 10, 2024 | Mohan Raju | Executive | Option Exercise | 96,778 | $0.20 | $19.4K | |
| Apr 12, 2024 | III Gp Llc Nsv Partners | Executive | Other | 695,339 | $N/A | $0 | |
| Apr 12, 2024 | Subramaniam Somu | Executive | Other | 695,339 | $N/A | $0 | |
| Apr 2, 2024 | Auster Martin | Executive | Sale | 1,405 | $5.40 | $7.6K | |
| Apr 2, 2024 | Mohan Raju | Executive | Sale | 4,312 | $5.40 | $23.3K | |
| Apr 2, 2024 | Nuss John | Executive | Sale | 1,651 | $5.40 | $8.9K | |
| Apr 2, 2024 | W. Krueger Christopher | Executive | Sale | 1,651 | $5.40 | $8.9K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 175 | $139.2M | 85.5% |
Purchase(P) | 3 | $20.0M | 12.3% |
Exercise(M) | 59 | $3.6M | 2.2% |
Award(A) | 2 | $4.9K | 0.0% |
Other(J) | 16 | $0 | 0.0% |
Gift(G) | 1 | $0 | 0.0% |
Conversion(C) | 6 | $0 | 0.0% |
Insider selling pressure at Ventyx Biosciences, Inc. has increased, with 16 insiders executing 262 transactions across all time. Total sales of $139.2M significantly outpace purchases of $20.0M, resulting in a net outflow of $119.2M. This selling activity appears largely discretionary, which may warrant closer attention from investors.